Bone Biologics Corp Dossier
Qualitative Analysis
Business overview
Bone Biologics Corp (NASDAQ: BBLG) is a clinical-stage medical device and biotechnology company focused on bone regeneration and orthobiologic products for the spine fusion market. The company's core platform technology centers on the recombinant human protein known as NELL-1, which is exclusively licensed worldwide from the UCLA Technology Development Group. Its lead product candidate, NB1, combines the osteopromotive rhNELL-1 protein with a demineralized bone matrix (DBM) to provide target-specific, guided control over bone regeneration. This technology is designed to improve surgical outcomes in spinal fusion procedures, particularly for challenging "hard healers," with additional potential applications in trauma and osteoporosis.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Thoughtful progression of the clinical development efforts for lead product candidate NB1 (rhNELL-1/DBM fusion device) for use in lumbar spinal fusion, including the ongoing multicenter pilot study in Australia.
Expected impact: Establish safety and efficacy data to support regulatory submissions and strategic partnership discussions.
Improving product readiness and manufacturing flexibility by extending the validated shelf life of the rhNELL-1 protein product through third-party stability testing.
Expected impact: Provides greater flexibility in lot sizing, distribution planning, and supply-chain management ahead of future pivotal studies.
Prioritizing capital allocation to the most promising assets and maintaining tight cost controls to manage cash burn rate while pursuing additional debt or equity financing.
Expected impact: Extends the operational runway and ensures sufficient funding to reach key clinical inflection points.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Bone Biologics with exclusive worldwide rights to develop and commercialize the NELL-1 technology platform for spinal fusion, osteoporosis, and trauma applications.
Terms: Subject to royalty and milestone payments under the technology transfer agreement.
MTF Biologics is a major shareholder and strategic partner that supplies demineralized bone matrix (DBM) to serve as the carrier for the rhNELL-1 protein in the NB1 combination device.
Terms: Exclusive supply terms for DBM carrier material.